Encouraging Results from Clinical Trials Drive Investments in hESC Research, According to New Report by Global Industry Analysts, Inc.
San Jose, California (PRWEB) July 05, 2012
Follow us on LinkedIn – Stem cells based therapies for various incurable degenerative diseases have been an exciting aspect of scientific research. The concept of using one’s own cellular building blocks in regenerating aging or damaged organs has enticed the scientific community for several years. At the outset, the recent years can be dubbed as one of the most eventful periods in the development history of stem cell therapies. The world, in recent years, witnessed the first ever stem cell therapy being approved, when the Korea Food and Drug Administration permitted the marketing of FCB-Pharmicell’s stem cells-based acute myocardial infarction therapy. Although this development is a major milestone in the area of regenerative therapy and stem cell based treatments, overall industry is still in its early days. The embryonic stem cell therapy continues to lag behind the adult stem cell research. Wilted by ethical, legal, and technical concerns, the human embryonic stem cells therapy area is moving at a relatively sluggish pace.
Far from witnessing the first launch of a therapy from this space, the area has even witnessed its foremost player, Geron, quitting the development of the first human embryonic stem cell (hESC)-based product ever to human clinical trials worldwide. This was a major setback to the embryonic stem cell space which is currently battling several issues such as potential threat to research work in the European region. However, other companies involved in this space are continuing their efforts unfazed and are nearing human clinical trials for their products. Advanced Cell Technology became the second company to obtain US FDA approval to commence human clinical trials for its hESC products in the US. Areas currently under study include cardiovascular diseases, neurological diseases, bone injuries and other skeletal defects, and diabetes.
Embryonic stem cells represent a type of stem cells that are extracted from an embryo, even before these cells begin to differentiate into other cells. These cells can be differentiated into virtually any type of cells including nerve cells and muscle cells. Although embryonic stem cells hold tremendous prospects in the area of regenerative therapy, the cells are marred with issues such as cell rejection by the host’s immune system due to histo-incompatibility as well as potential for development of tumors. These cells, at the development stages, also face issues such as potential contamination of embryonic stem cells with animal products that are used in the cell culture. These hurdles are required to be addressed for further advancement in therapies based on human embryonic stem cells. One of the major advantages of hESCs that keep researchers glued to this industry despite prevailing hurdles is the pluripotency of these cells or their ability to develop into any other type of cell in the human body. Although promising in its potential, the area has been laced with significant controversies and technical hurdles that paved way for more focus on adult stem cells. However, public opinion stands firm on hESCs. Recent opinion polls carried out in the US with respect to embryonic stem cells have given an improving picture of public acceptance of this technology. On a positive note, human embryonic stem cell research continues to move ahead with investments in this area growing each year.
The US represents the largest regional market for human embryonic stem cell (hESC) research worldwide, as stated by the new market research report on Human Embryonic Stem Cell (hESC) Research. Europe represents the second largest regional market worldwide. However, growth in the global hESC research market is projected to be driven by the US. Favorable regulatory environment in the US, such as lifting the ban on federal funding in this area is driving this market. Several new stem cell lines have been generated ever since the ban was lifted and many companies are engaged developing therapies based on embryonic stem cells. Favorable trends are also emerging from countries such as South Korea, where a ban on stem cell research has been lifted and research in this area is gaining momentum. Significant unmet needs exist among various therapeutic areas, continuing to fuel interest in the area of embryonic stem cells. Uncertainty, however, stems from the European region in the wake of recent ban imposed by the EU on patents on embryonic stem cells.
Major players profiled in the report include Advanced Cell Technology, Inc., BioTime, Inc., Cellartis AB, Molecular Transfer, Inc., PerkinElmer, Inc., Pfizer, Inc., Stem Cell Network, ViaCyte, Inc., among others.
The research report titled “Human Embryonic Stem Cell (hESC) Research: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides comprehensive market overview, trends & issues, regulatory landscape, major application areas, recent industry activity and profiles of market players worldwide. Analysis and overview is provided for the years 2009 through 2018, for major geographic markets, such as US, Europe and Rest of World. Market analytics are provided in terms of annual investments in US$ Million.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.
Follow us on LinkedIn
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Find More Building Muscle Press Releases